AI-guided Target Prioritization and Early Trial Design

R&D teams face an overload of candidate targets from screening experiments, public genomics, and published studies but limited resources to validate them. This leads to slow lead selection, costly failed IND-enabling programs, and uncertainty about the right biomarkers and patient segments for small-scale trials.

Combine representation learning, causal analytics, and human review to convert heterogeneous biomedical signals into prioritized actions and trial blueprints.

• Ingest and harmonize data (omics, preclinical assays, EHR/claims, adverse event databases, and full-text literature) with a governed pipeline and standardized ontologies.
• Use graph neural networks and multimodal embeddings to map target-disease-biomarker relationships and score mechanistic plausibility and translational potential.
• Apply causal inference and simulation to estimate effect sizes in candidate patient segments and to design sample-size, endpoint, and inclusion criteria options for Phase I/II trials.
• Present ranked targets and trial design variants in a human-in-the-loop review workflow (scientists, clinicians, statisticians) with explainability artifacts and validation tests against historical programs.
• Enforce governance: bias checks, data provenance logs, de-identification/federated learning for patient data, and prospective prospective validation plans.

Illustrative impact: teams typically reduce the number of low-probability targets taken into IND-enabling work by 20-50% and can shorten lead selection timelines by 3-9 months. Early-phase trial designs informed by these models often reduce required screening cohorts and budget uncertainty, yielding an illustrative 10-30% reduction in early development cost and clearer go/no-go signals; actual results depend on data quality, governance maturity, and domain complexity.